Additionally, if blood pressure control is a concern, the 2024 European Society of Cardiology (ESC) hypertension guidelines now classify beta-blockers as an alternative treatment to angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), angiotensin receptor-neprilysin inhibitors (ARNIs), calcium channel blockers (CCBs), diuretics, and sodium-glucose cotransporter-2 (SGLT2) inhibitors [5]. Here, SLC5A2 is linked to hypertensive disorder.